ESYT2

Across TCGA pan-cancer cohorts, ESYT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ESYT2 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ESYT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ESYT2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where ESYT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.144	0.964	.008	26	view →
CCRCC	OS	Median	II,III,IV	0.454	1.000	.014	9	view →
LSCC	OS	Median	All	0.922	1.000	.011	8	view →
LUAD	DFS	Median	II,III,IV	0.234	0.821	.010	7	view →
GBM	DFS	Tertile	All	0.900	0.551	.004	3	view →
PDAC	DFS	Quartile	All	0.713	0.974	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ESYT2–HNSC (OS)

Open the HNSC breakdown →